Sean Berquist, MD

Disclosure information not submitted.

Presentation(s):

• PD38-01: Feasibility, safety and efficacy results of the SUFU Foundation open label clinical trial of ultrasound confirmed transvaginal botulinum toxin A (BTA) for refractory overactive bladder (OAB)

  Sunday, May 15, 2022
  7:00 AM – 7:10 AM